The Treatment of Symptomatic Benign Breast Disease with Danazol

George Ramsey‐Stewart
In: Australian and New Zealand Journal of Obstetrics and Gynaecology · 1988 · vol. 28(4) , pp. 299–304 · doi:10.1111/j.1479-828x.1988.tb01686.x · PMID:3074777 · W2072631596
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

Danazol treatment of 80 women with severe cyclical symptomatic benign mammary dysplasia showed significant improvement in breast pain, tenderness, and nodularity compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

EDITORIAL COMMENT: Breast disease should concern all obstetricians and gynaecologists as well as general practitioners, since patients often report their breast symptoms at the time of attendance for a Papanicolaou smear. It is natural that the patient expects the one practitioner to advise her regarding prevention/ early diagnosis of cancer of the breast and cervix. Since 5–8% of women develop carcinoma of the breast and fewer than 1 in 10 breast lumps are found on biopsy to be malignant, breast pathology is too common and important to be ignored in this journal. The more common symptoms of breast pain and tenderness also warrant consideration. Many patients with breast symptoms require only reassurance, although the investigations available for screening for breast cancer will often require discussion (1). Summary: A prospective randomized double blind trial, using danazol in a dose of 200 mg twice a day, was carried out on 80 women presenting with severe cyclical symptomatic benign mammary dysplasia. Standardized scores for 4 parameters of disease severity (breast pain, breast tenderness, breast nodularity and breast cysts) were defined and measured monthly on all patients admitted to the trial. Using nonparametric statistical analysis, significant improvement in breast pain, tenderness and nodularity, was found in both the double blind and crossover arms of the trial. An insufficient number of patients presented with breast cysts to draw any conclusions regarding the efficacy of danazol on cysts. Six months of treatment may produce a more sustained response, than 3 months of treatment. Danazol appears to be efficacious in managing patients with severe breast symptoms due to benign disease.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-11T06:10:27.824888+00:00
License: CC0 · commercial use OK